NEUWAY is pursuing its own developments (see disease areas), but we are also interested in partnerships and co-developments for other indications. With these partnerships we want to broaden the use of EPCs as a tool for drug delivery to the brain. In addition, NEUWAY has under development a vaccination candidate (NWP007) and is preparing the start of the clinical development for this new drug.
For these two different approaches for the use of NEUWAY’s EPC, we are interested in:
- Partnering NWP007 for its use as a therapeutic vaccine to treat progressive multifocal leukoencephalopathy (PML). This compound may also be developed as a prophylactic vaccine in patients at high risk to develop PML.
- Application of its proprietary CNS Drug Delivery Technology to proprietary compounds of partners to facilitate their transport through the blood-brain-barrier.
NEUWAY has a flexible approach to deal structuring and aims to create relationships that maximize the value for both parties.
Please direct any inquiries to:
Dr. Rudi Scherhag
Chief Operating Officer
Phone: +49 (0)228 522798-12